.avif)
Sunovion Pharmaceuticals Email Format
Pharmaceutical Manufacturing
・
1,001-2,500 employees
・
Marlborough, MA, USA
Sunovion Pharmaceuticals is a pharmaceutical company that develops and commercializes therapies for central nervous system disorders, respiratory diseases, and oncology in the United States and globally.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@sunovion.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
2010
Headquarters
Marlborough, MA, USA
Revenue
$250M-$500M
FUNDING Stage
Subsidiary
Website
Key Executives
Tsutomu Nakagawa (President and Chief Executive Officer), Ron Gimbel (Chief Financial Officer), Andrew Hetherington (Chief Technology & Quality Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Sunovion Pharmaceuticals?
Sunovion Pharmaceuticals uses the first.last format on sunovion.com, so Jane Smith would be jane.smith@sunovion.com.
What are Sunovion Pharmaceuticals' primary therapeutic areas?
Sunovion Pharmaceuticals focuses on central nervous system disorders and respiratory conditions, with marketed products including Latuda for schizophrenia and bipolar I depression, Lunesta for insomnia, and Brovana and Xopenex for respiratory disease.
How can I find and verify the right contact at Sunovion Pharmaceuticals for a medical affairs outreach?
Because Sunovion Pharmaceuticals follows the first.last@sunovion.com format, tools like Clay can help you build and verify contact emails for specific Sunovion teams, including medical affairs, by combining a contact's name with the confirmed domain.
Latuda is one of Sunovion Pharmaceuticals' best-known drugs -- what conditions does it treat?
Latuda, known generically as lurasidone, is an atypical antipsychotic approved by the FDA to treat schizophrenia in adults and adolescents and major depressive episodes associated with bipolar I disorder in adults.
Who leads Sunovion Pharmaceuticals as its chief executive?
Tsutomu Nakagawa serves as President and Chief Executive Officer of Sunovion Pharmaceuticals, with Ron Gimbel as Chief Financial Officer and Andrew Hetherington as Chief Technology and Quality Officer rounding out the senior leadership team.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating